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To the editor:
Common variable immune deficiency (CVID) is a primary
antibody deficiency characterized by a marked decrease of im-
munoglobulin (Ig) G in combination with low IgA and/or IgM,
an impaired response to immunization and recurrent infections
[1]. Up to 68% of CVID patients have additional noninfectious
complications (NIC), including autoimmune complications, ma-
lignancies, and granulomatous disease. These NIC are associated
with increased morbidity and mortality [2–4]. Granulomatous
disease, especially granulomatous and lymphocytic interstitial
lung disease (GLILD), leads to a significant reduction in median
survival in CVID patients [5]. Granuloma formation is thought to
be initiated by CD4+ T lymphocytes that become activated after
interaction with antigen presenting cells [6]. Activated CD4+ T
lymphocytes secrete cytokines that subsequently stimulate mac-
rophage activation and tumor necrosis factor (TNF)-α produc-
tion, ultimately leading to the characteristic immune cell agglom-
erates (i.e., granulomas) in various organs.
Several studies have tried to identify potential biomarkers for
NIC in CVID. It has been shown that increased numbers of PD-1
high CCR7 low CD4+ T follicular-helper-lymphocytes are asso-
ciated with autoimmune complications or granulomatous disease
[7]. Furthermore, an association between elevated serum IgM
and interstitial lung disease in CVID, which was related to B cell
follicles within the lung parenchyma, is reported [8]. In pediatric
CVID patients, it was observed that reduction in total B and NK
lymphocytes with an increase in CD8+ T lymphocytes was as-
sociated with presence of bronchiectasis [9]. Hartono et al. [10]
described a prediction model for the presence of GLILD in
CVID. They showed that a medical history of splenomegaly,
immune thrombocytopenia (ITP) and/or autoimmune hemolytic
anemia (AIHA), IgA levels < 13 mg/dl, and CD21-low B lym-
phocytes > 5% of total CD21 B cells are to be predictive mea-
sures for GLILD in CVID [10].Wewere interested to seewheth-
er these clinical and immunological features were also predictive
for GLILD in our CVID cohort. Therefore, we collected data on
the presence of splenomegaly, ITP, AIHA, the IgA levels, and
the frequency of CD21-low B lymphocytes from our cohort of
CVIDpatients, which resulted in a subgroup of 38CVIDpatients
of which all these characteristics were available. In our cohort,
only the presence of splenomegaly was found to be significantly
increased in patients with GLILD when compared to CVID pa-
tients without GLILD. Moreover, also in patients with granulo-
matous complications affecting other organ systems, including
spleen and lymph nodes, only splenomegaly positively correlat-
ed with the presence of granulomatous disease (Supplementary
Table 1). However, it has to be taken into account that sample
sizes used for analysis were small.
These findings prompted us to search for a low-invasive bio-
marker to diagnose and monitor the progression of granuloma-
tous disease in CVID. The soluble form of the interleukin-2
receptor (sIL-2R or sCD25), which is secreted by activated T
lymphocytes, is frequently used to monitor immune cell activa-
tion. Elevated sIL-2R levels have been reported in various path-
ological conditions, including autoimmune diseases, infection,
and malignancies [11–14]. Previous studies showed that sIL-
2R levels in CVID patients in general are higher than in healthy
controls (HCs) [15–17]. Moreover, it has been demonstrated that
sIL-2R levels are higher in CVID patients with NIC when com-
pared to patients with infections-only (IO), or CVIDpatientswith
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gastrointestinal symptoms [18, 19]. Furthermore, a decline of
sIL-2R was found to coincide with clinical improvement after
abatacept treatment in patients with CTLA-4 haploinsufficiency
and lipopolysaccharide responsive beige-like anchor protein
(LRBA)-deficiency [7, 20, 21].
The relation between sIL-2R level and granulomatous dis-
ease in CVID patients has not been extensively studied. Only
one case study described a decline of serum sIL-2R in a CVID
patient with granulomatous lung diseases after effective immu-
nosuppressive therapy with azathioprine and rituximab [22]. In
sarcoidosis, an inflammatory multisystem granulomatous dis-
ease of unknown etiology, serum sIL-2R, was reported as a
sensitive biomarker [23, 24]. Therefore, we aimed to determine
whether serum sIL-2R level can be used as a low-invasive
biomarker for detection of granulomatous disease and for mon-
itoring granuloma progression or remission in CVID patients.
To this aim we performed a retrospective single-center anal-
ysis, evaluating serum sIL-2R levels in 48 CVID patients, in-
cluding 12 patients with granulomatous disease, 13 healthy
controls (HC), and 79 sarcoidosis patients previously reported
by our group (Supplemental Table 2 and the method section in
the supplemental data) [23]. Similar to the previous studies, the
CVID group displayed significantly higher sIL-2R levels (me-
dian sIL-2R 4,539 pg/ml; range: 1,037–48,875 pg/ml) com-
pared to the HC group (median sIL-2R 1,419 pg/ml; range:
1,096–3,328 pg/ml) (Supplemental Fig. 1a, Supplemental
Table 2) [15, 17, 18]. The variability of sIL-2R levels observed
within the CVID group was not related to the type of immuno-
globulin replacement therapy, since no significant difference
was observed in sIL-2R levels across the various treatment
modalities (Supplemental Fig. 1b). Interestingly, the group of
CVID patients with NIC (CVID+NIC, n = 22) had significantly
higher sIL-2R levels (median: 6,612 pg/ml; range: 1,620–
48,875 pg/ml) than the CVID group with IO (CVID IO; n =
26; median sIL-2R: 2,918 pg/ml; range: 1,037–17,300 pg/ml)
or HC (Supplemental Fig. 1c, Supplemental Tables 2 and 3).
This is in line with a previous study that showed significantly
higher sIL-2R levels in CVID patients with NIC, compared to
CVID patients with infections only or HC [18].
To determine whether CVID patients with granulomatous
disease have increased levels of sIL-2R, we compared sIL-2R
levels prior to and at the time when there was reported progres-
sion of granulomatous disease (CVID+p.granuloma) with CVID
patients with IO. Data on progression of granulomatous disease
were derived from clinical reports, computed tomography (CT)
scan, magnetic resonance imaging (MRI) or pathology reports
from patient files. Interestingly, the CVID+granuloma group
(median sIL-2R: 10,853 pg/ml; range: 4,458–13,049 pg/ml)
displayed significantly higher serum sIL-2R levels than CVID
IO (Fig. 1a). Moreover, sIL-2R levels increased upon progres-
sion of granulomatous disease (CVID+p.granuloma, median
sIL-2R: 22,274 pg/ml; range: 5,476–48,875 pg/ml) (Fig. 1a).
Also, median levels of sIL-2R in both CVID+granuloma and
CVID+p.granuloma were higher than the median levels we pre-
viouslymeasured in sarcoidosis patients (n= 79; median sIL-2R:
6,000 pg/ml; range: 1,600–90,300 pg/ml), only reaching statisti-
cal significance for CVID+p.granuloma (Fig. 1a, Supplemental
Table 2) [23].
To further determine whether serum sIL-2R could be used to
differentiate between CVID patients with progression of granu-
lomatous complications and other CVID patients, a Receiver
Operator Curve (ROC) analysis was performed (Fig. 1b,
Supplemental Fig. 1d). This revealed that serum sIL-2R can be
used to differentiate between CVID+p.granuloma and CVID IO
(area under the curve (AUC) = 0.95) (Fig. 1b, Supplemental
Table 4). Using a cutoff value for sIL-2R of > 6,376 pg/ml,
yielded a high sensitivity of 91.7% and a high specificity of
88.5% with a Youden’s Index (YI) of 0.80 to differentiate be-
tween CVID+p.granuloma and CVID IO. These findings sug-
gest that high sIL-2R level (> 6,376 pg/ml) might represent a
clinically valuable biomarker to differentiate CVID patients with
granulomatous complications from other CVID patients.
The clinical context of the patient of which serum sIL-2R
level is measured and interpreted is important, since sIL-2R is
increased in many inflammatory diseases or complications [14].
Therefore, the sensitivity is predicted to be high, while specificity
is low. To evaluate whether an increase of sIL-2R levels was
associated with other inflammatory complications, clinical pro-
files of the included patients were studied, focusing on additional
inflammatory complications, including presence of bronchiecta-
sis, ground glass lesions, lymphoproliferation, splenomegaly,
and intestinal complications, at time of serum sampling. No as-
sociation was observed between other inflammatory complica-
tions and sIL-2R levels (Supplemental Table 3).
Although overlap existed in sIL-2R levels between sarcoid-
osis and CVID+p.gran, in general, sIL-2R levels in sarcoidosis
were lower (median 6,000 pg/ml) than in CVID+p.gran (medi-
an 22,274 pg/ml) (Supplementary Table 2). We observed that
serum sIL-2R could differentiate between CVID+p.granuloma
and sarcoidosis with a sensitivity of 91.1%, specificity of 41.7%
and YI from 0.33 using a cutoff value of < 23,223 pg/ml. This
indicated that sIL-2R levels lower than 23,223 pg/ml are as-
sociated with lower probability of having granulomatous dis-
ease progression in CVID, but rather may be indicative for
sarcoidosis, a granulomatous disease CVID patients can be
misdiagnosed with. Therefore, additional diagnostics such as
serum immunoglobulin levels should be performed to rule out
the diagnosis of sarcoidosis [25].
Since we observed increasing sIL-2R levels upon progres-
sion of granulomatous disease (Fig. 1a), we further analyzed
longitudinal serum sIL-2R measurements of six CVID pa-
tients with granulomatous disease of which longitudinal data
were available. Interestingly, sIL-2R levels increased in all
patients when progression of granulomatous disease was clin-
ically observed (Fig. 1c). Moreover, a decrease in sIL-2R
levels was observed after effective treatment with rituximab,
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prednisone, or prednisone in combination with methotrexate
(Fig. 1c). This further strengthens the previous notion that
serum sIL-2R can be used to monitor the effect of treatment
for granulomatous disease in CVID [22]. In patient 6, the sIL-
2R levels also increased during a second episode of collagen
colitis, which supports the previous findings of increased sIL-
2R levels in patient with gastrointestinal symptoms [19].
Of note, the baseline levels of sIL-2R levels were different
for each CVID patient. This suggests that it is important to
regularly monitor sIL-2R levels in order to timely detect an
increase in serum sIL-2R relative to the patient baseline sIL-
2R level. Although sIL-2R is related to many immune-
regulated processes, an increase could reflect development
or progression of granulomatous disease.
In summary, our data indicate that in patients with CVID
sIL-2R levels rise with progression of granulomatous disease.
On the other hand, sIL2R levels decline upon remission of
granulomatous disease after treatment. These observations
suggest that sIL-2R levels can be used as monitoring tool for
evaluation of progression and treatment efficacy of granulo-
matous disease in CVID.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s10875-020-00947-8.
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Fig. 1 Discriminative capacity of serum sIL-2R. a sIL-2R levels per
subgroups of CVID (CVID IO (IO, n = 26); CVID+granuloma (+gran,
n = 12); CVID+progression of granulomatous disease (+p.gran, n = 12)
and sarcoidosis (sarc, n = 79). b ROC-curves showing discriminating
capacity of sIL-2R. Black lines indicate median, square symbols are
CVID patients with multiple NIC. c Longitudinal sIL-2R analysis of 6
CVID+granuloma patients. sIL-2R levels are showed per years after start
sampling (first time point) of sIL-2R. Blue gradient indicates progression
of granulomatous disease derived from patient files. Green arrows shown
in patient 3 until 6 indicate start of antigranuloma treatment. The red
gradient indicate episodes of collagen colitis in patient 6
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